Limited available data with SOLOSEC use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. In animal reproduction studies, there were no adverse developmental outcomes when secnidazole was administered orally to pregnant rats and rabbits during organogenesis at doses up to 4 times the clinical dose.
Breastfeeding is not recommended. Discontinue breastfeeding for 96 hours after administration
Please log in to ObGFirst to access the 2T US Atlas